Commentary
Despite the recent rapid accumulation of knowledge about the genetics and mechanisms of Alzheimer disease (AD), and the creation of transgenic mouse models of AD, at present there is no complete animal model for AD (Ashe and Zahs, 2010) nor any FDA approved truly disease-modifying drug available. Frustration based on these limitations is palpable in this volume, especially in view of early expectations of effective therapy based on the amyloid hypothesis, which have not been born out (Fleisher et al., 2008; Holmes et al., 2008) . We may need new paradigms concerning disease pathogenesis and progression to develop more targeted agents, and the ability to test these agents during the predementia mild cognitive impairment (MCI) or even earlier in cognitively intact individuals at risk (Reiman et al., 2004; Snowdon et al., 2000) . This special issue on ''Biomarkers for Neurodegenerative Disorders'' provides up-to-date insights by experts on which biomarkers might be most useful for identifying factors disturbed in MCI and AD, for the differential diagnosis of AD, and for evaluating drug efficacy in the disease.
AD as the cause of a dementia must be confirmed by postmortem evidence of brain accumulation and distribution of senile (neuritic) amyloid plaques (SPs) containing condensed bamyloid peptide, and of neurofibrillary tangles (NFTs) consisting of paired helical filaments of phosphorylated tau protein. Using this definition, we might step back and consider aspects of AD related to brain evolution that are not emphasized in this biomarker volume.
AD appears to be a uniquely human disease, since comparable levels of SPs plus NFTs have not been identified in brain in any natural animal model, although transgenic manipulation with human genes has produced selective AD-like changes in rodents (Ashe and Zahs, 2010) . Human uniqueness may be related to the fact that AD neuropathology, but particularly the NFTs (Braak and Braak, 1996) , is concentrated in certain brain regions with long axonal connections, which the fossil record and comparative neuroanatomy (Stephan, 1983) suggest selectively expanded during primate but particularly hominid evolution, by a process termed ''integrated phylogeny' ' (Rapoport, 1990) . These regions include association neocortex and parts of the entorhinal cortex, amygdala (basolateral nuclear group), hippocampal formation (CA1 region and subiculum) and nucleus basalis of Meynert, with which the association cortex formed new connections. High CSF levels of tangle-related total tau protein and phosphorylated tau in MCI and AD are consistent with this evolutionary history for regional vulnerability to AD (Hampel et al., 2010) . Further, the evolution of the native structure of tau proteins could be partly responsible for the interspecies differences in vulnerability to developing NFTs (Nelson et al., 1996) .
During postnatal and adult human development, the cycles of myelination in different regions of the brain are consistent with their differential expansion during primate evolution, with some cortical regions of the AD-vulnerable telencephalic system myelinating beyond 30 years of age (Braak and Braak, 1996;  Brain regions and their highly neuroplastic long axonal connections that expanded rapidly during hominid evolution are preferentially affected by Alzheimer disease. There is no natural animal model with full disease pathology (neurofibrillary tangles and neuritic amyloid plaques of a severity seen in Alzheimer's disease brains). Biomarkers such as reduced glucose metabolism in association neocortex, defects in long white matter tracts, RNA neurochemical changes, and high CSF levels of total and phosphorylated tau protein, which are helpful to identify MCI and preclinical Alzheimer disease patients, may also provide insights into what brain changes led to this disease being introduced during hominid evolution.
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